Trials / Completed
CompletedNCT04933682
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
A Phase 1 Two-Part Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Fluconazole, and Between ALXN2050 and Rifampin in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in healthy adult participants. Part 1 will be a 2-period, fixed-sequence study. Part 2 will be a single-period, fixed-sequence study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN2050 | Oral tablet. |
| DRUG | Fluconazole | Oral tablet. |
| DRUG | Rifampin | Oral capsule. |
Timeline
- Start date
- 2021-06-23
- Primary completion
- 2021-08-04
- Completion
- 2021-08-04
- First posted
- 2021-06-22
- Last updated
- 2022-12-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04933682. Inclusion in this directory is not an endorsement.